On September 4, 2025, Salarius Pharmaceuticals, Inc. confirmed it regained compliance with Nasdaq's minimum bid price requirement, maintaining a price of $1.00 per share for 10 consecutive business days. The company is still working towards meeting another compliance standard by October 20, 2025.